Heart failure with reduced and preserved ejection fraction. Clinical and translational aspects

Heart failure affects 2-3% of the Western population and with an ageing population, this prevalence will grow.

Lars Lund. Photo: Martin Stenmark
Lars Lund. Photo: Martin Stenmark

Lars H Lund Research Group



Lars Lund

Unit: Research group L Lund



Heart failure is associated with poor quality of life, is the most common cause of hospitalization and associated with high costs to society and high mortality.

Our group consists of multiple PhD students, post-docs and fellows, statisticians and data mangers, and research nurses. We also collaborate with other groups at Karolinska, throughout Sweden, and globally. We are involved in epidemiological, clinical and molecular aspects of heart failure. For group constellation and members, please see: https://medarbetare.ki.se/orgid/520225

The registry-based, big data and epidemiology research is led by Gianluigi Savarese, MD, PhD.

The HFpEF program, phase 2 trials, biomarker and imaging research is led by Camilla Hage, RN, PhD.

Highly qualified and motivated individuals interested in pursuing mechanistic, clinical or registry based research in the field of heart failure are welcome to contact our group.

Specific interests:

1. Registry based research in heart failure, using the Swedish Heart Failure Registry (SwedeHF; see https://kiheartfailure.github.io/shfdb3/) and the ESC heart failure registries (HF-LT and HF III).

2. Designing and conducting pragmatic and registry based randomized controlled trials (RCTs and RRCTs) in heart failure, focusing on drug repurposing and new-use concepts for existing generic drugs. SPIRRIT-HFpEF is the first pragmatic trial in HFpEF, see https://www.ucr.uu.se/rikssvikt/rrct/spirrit-hfpef

3. Heart failure with mildly reduced ejection fraction (HFmrEF): characterization and testing whether HFrEF therapy may be beneficial also in HFmrEF.

4. Heart failure with preserved ejection fraction (HFpEF): risk factors, comorbidity and cause specific morbidity and mortality; focus on novel mechanisms and targets, including comorbidity driven systemic inflammation and microvascular dysfunction; and interventional trial design.

5. Heart failure with reduced ejection fraction (HFrEF): novel mechanisms for contractility; discovering novel targets and developing novel treatments targeting contractility: inotropes, myotropes, calcium sensitizers.

6. Physiologic, neurohormonal and metabolic aspect of heart failure with preserved and reduced ejection fraction, and effects of heart transplantation and mechanical circulatory support (LVAD and ECMO).

7. Early phase (phase 2) human interventional trials of existing drugs for novel indications (repurposing) and of novel drugs and peptide hormones as treatment for heart failure.

8. Implementation science: How to optimize utilization of existing therapy for heart failure with reduced ejection fraction.